M62.81 classifies a reduction in muscle strength across multiple anatomic sites that is not attributable to a more specifically coded neuromuscular or systemic disorder.

Documentation tips

What should appear in the chart to support M62.81.

Source · Editorial brief grounded in 7 cited references ↓

• Record objective strength measurements — Manual Muscle Testing (MMT) scores at each tested region — to substantiate 'generalized' weakness and defend the code against audit.
• Document the distribution of weakness explicitly: name the multiple body regions affected so the note supports 'generalized' rather than localized weakness.
• State the clinical context driving the weakness (e.g., post-ICU deconditioning, prolonged bed rest following surgery, chemotherapy course) and code the underlying cause first when it is codeable.
• Include functional impact — ADL limitations, gait deficits, inability to perform transfers or stairs — to justify the medical necessity of associated therapy services.
• If sarcopenia, a specific myopathy, or a defined neuromuscular diagnosis is confirmed anywhere in the record, use that code instead of M62.81; document why M62.81 is appropriate if the more specific condition is not confirmed.
• For therapy plans of care, include a progress reporting schedule and link each billed CPT service directly to the documented deficits — payers audit whether the note justifies the billed services.

Related CPT procedures

Procedure codes commonly billed with M62.81. Linking the right diagnosis to the right procedure is what establishes medical necessity.

Source · CMS LCDs · AAOS specialty guidance · claims-pattern analysis

Common coding pitfalls

The recurring mistakes coders make with M62.81 and adjacent codes.

Source · Editorial brief grounded in CDC ICD-10-CM tabular guidance, AAOS coding references, and cited references ↓

• Coding M62.81 for localized weakness: this code requires weakness across multiple anatomic sites; single-region weakness belongs in the M62.5x atrophy family or a site-specific code.
• Using M62.81 alongside R53.1 (Weakness/Asthenia NOS): these codes have a Type 1 Excludes relationship — they cannot appear on the same claim.
• Downcoding confirmed sarcopenia (M62.84) to M62.81: when the provider documents sarcopenia, M62.84 is required; M62.81 is not an acceptable substitute.
• Failing to code the underlying condition first: ICD-10-CM convention directs coders to sequence the causative diagnosis (e.g., inflammatory myopathy, neurological disorder) before M62.81.
• Billing M62.81 with CPT services whose medical necessity requires a stronger clinical story than the note provides — claims deny when the documented deficits do not clearly justify the billed procedure.
• Relying on 'patient is weak' as the only documentation; without objective MMT scores, functional limitations, and multi-region distribution, the code is undefendable on audit.

Clinical context

Source · Editorial summary grounded in 7 cited references ↓

Inclusion & exclusion notes

Per the official ICD-10-CM Tabular List.

Source · CDC ICD-10-CM Official Tabular List · 2026

Sibling codes

Other billable codes under M62.8 (laterality / anatomic variants).